ContractTransitional Manufacturing and Supply Agreement • May 18th, 2012 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations • Quebec
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO CERTAIN PORTIONS OF THIS AGREEMENT. CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Amendment No. 2 to TRANSITIONAL MANUFACTURING AND SUPPLY AGREEMENTTransitional Manufacturing and Supply Agreement • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations
WHEREAS, Supplier and Prestige entered into a Transitional Manufacturing and Supply Agreement dated January 31, 2012, as amended by Amendment Number One to the Transitional Manufacturing and Supply Agreement dated as of June 25, 2013 (collectively, the “Agreement”), whereby Supplier agreed to supply and Prestige agreed to purchase certain products (“Products”); and
AMENDMENT NUMBER ONE TO THETransitional Manufacturing and Supply Agreement • May 17th, 2016 • Prestige Brands Holdings, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE to the Transitional Manufacturing and Supply Agreement (the "Amendment") is made and entered into as of the 25th day of June, 2013, by and between GlaxoSmithKline Consume1· Healthcare L.P., a Delaware limited liability company ("GSK"), and Medtech Products Inc., a Delaware corporation ("Buyer").
